ClinicalTrials.gg
RecruitingNCT05370820Optimum OB-TXAUpdated Oct 16, 2026

Prevention of Postpartum Hemorrhage With Tranexamic Acid

A Phase 2 interventional study of Tranexamic acid and Tranexamic acid in Post Partum Hemorrhage, sponsored by Inova Health Care Services. Recruiting at 2 sites in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Inova Health Care Services · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 10 months later.
Updated Oct 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage — 8 open to participants now, 8 under way, 3 of them phase 3. Tranexamic Acid · Postpartum Hemorrhage.

Planned enrollment
32nd of 50
120 · median 198
Started
2022
with 2 others
Phase 2
6 of 50
1 open now
Registered
36th of 50
by date

Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, this one is the 32nd largest by planned enrollment, is one of 3 that started in 2022, is one of 6 in phase 2, and was the 36th registered.

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

8 of the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage are open now, in 8 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, or all of them as a file.
02

Study summary

In part 1 of the study, the investigators conducted a prospective, open-label, dose finding pharmacokinetic (PK) study in 43 pregnant 3rd trimester women scheduled for non-emergent cesarean section.

The investigators administered three doses of the drug (5 mg/kg, 10 mg/kg and 15 mg/kg) in an escalating fashion by cohort with the lowest dose first. The drug was administered intravenously at the time of umbilical cord clamping for a non-emergent cesarean section. A maximum of 1 g was administered. TXA serum levels at several time points after delivery were assayed to see if they reach the target plasma concentration of 10 ug/mL. A PK model was constructed for determining the optimal TXA dose administered at parturition.

In part 2 of the study, the investigators aim to compare PKPD endpoints using prophylactic TXA via IV and IM routes administered pre-cord clamp. The investigators will administer 1 g TXA within 10 minutes of skin incision via intravenous infusion (up to n=15), intravenous bolus \< 2 minutes (up to n=15) and intramuscular injection (up to n=15). The investigators will target women undergoing scheduled cesarean delivery > 34 weeks gestation, women undergoing vaginal delivery > 34 weeks of gestation and morbidly obese women (BMI>=40) undergoing either a vaginal or cesarean delivery. The investigators will use advanced modeling techniques to determine time to achieve PKPD targets and duration remaining at those targets. The goal will be to determine how the optimal dose may vary if route of administration is modified. The investigators plan to enroll 45 patients in addition to the 43 that were enrolled during part 1. Our goal is to 30 participants, but the investigators will enroll 45 to account for lost to follow-up. The investigators also aim to enroll 30 patients undergoing vaginal delivery and 30 morbidly obese women (BMI >= 40) undergoing either a vaginal or cesarean delivery but the investigators will enroll 45 patients for each of these groups to account for loss to follow up. In addition, the investigators will enroll 30 pregnant patients receiving no medication acting as the control group, but the investigators will enroll 45 to account for loss to follow up.

Read the detailed description

The study will enroll 45 additional third trimester pregnant women scheduled for nonemergent cesarean sections. The investigators plan to enroll 30, but to account for lost to follow-up, the investigators will enroll 45. The investigators will also enroll 30 pregnant patients > 34 weeks of gestation undergoing vaginal delivery, and 30 morbidly obese (BMI >= 40) pregnant patients undergoing either vaginal or cesarean delivery. However, the investigators will enroll 45 patients in each of these two groups to account for loss to follow up. The investigators will also enroll 45 patients as a control group that will not receive TXA. The total number of enrolled patients will thus be 223.

A total of 1 g of TXA will be administered to patients prior to fetal delivery via three different routes of administration: IV infusion, IV push, and IM injection. The subjects in each group will be divided into three subgroups:

Group 1: Up to 15 subjects, TXA dose: 1 g, Route: IV infusion over 10 minutes Group 2: Up to 15 subjects, TXA dose: 1 g, Route: IV Push for \<2 minutes Group 3: Up to 15 subjects, TXA dose: 1 g, Route: IM Injection

Plasma sampling: Timing of samples will be relative to the end of drug administration (t = 0) and include: Pre-drug administration, 5-10 minutes, 30-60 minutes, 60-90 minutes, 1.5-3 hours, 3-4 hours, 4-5 hours, 7-8 hours, and 10-18 hours. Each volume of blood draw will be approximately 7-9 mL. Actual times of plasma sampling will be documented. A second IV will be required for participating in the study. Citrated plasma samples will be centrifuged and supernatant will be stored at -80 degree Celsius. Breast milk sampling of no more than 2 mL per time point will occur at time points coinciding with maternal feedings.

03

Conditions studied

  • Post Partum Hemorrhage

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women who are scheduled to under medically indicated cesarean section at greater than 34+0 weeks gestation or women who are scheduled to undergo an elective cesarean section at 39+0 weeks gestation in accordance with recommendations from the American Congress of Obstetricians and Gynecologists
  • Women who are indicated to have a vaginal delivery at > 34+0 weeks gestation.
  • Pregnant women with normal serum creatinine (serum creatinine \< 0.9) within 2 weeks of estimated/scheduled delivery
  • Women between the ages of 18 and 50 years old
  • Ability to understand and the willingness to sign a written form and HIPAA Authorization.

Exclusion criteria

Exclusion Criteria:

  • active thrombotic or thromboembolic disease
  • a history of arterial or venous thromboembolic event
  • inherited thrombophilia or preexisting conditions that predisposes them to thromboembolic events (i.e. lupus, antiphospholipid syndrome, thrombocytosis or thrombophilic thrombocytopathy)
  • a subarachnoid hemorrhage
  • acquired defective color vision
  • history of seizure disorder
  • known renal dysfunction (serum creatinine = or >0.9)
  • multiple gestations (twin or triplet pregnancies)
  • to Tranexamic acid or anti-fibrinolytic therapy
  • history of liver dysfunction at the discretion of the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Cesarean Delivery

    Drug: Tranexamic acid · Other: No intervention

  • Experimental
    Vaginal Delivery

    Drug: Tranexamic acid · Other: No intervention

  • Experimental
    Morbidly Obese

    Drug: Tranexamic acid · Other: No intervention

  • No intervention
    No TXA

Interventions

  • Tranexamic Acid 1000 mg administered intravenously via infusion over 10 minutes.

  • Tranexamic Acid 1000 mg administered intravenously via push over 2 minutes.

  • Tranexamic Acid 1000 mg administered intramuscularly.

  • OtherNo intervention

    Control group with no administration of Tranexamic Acid.

06

What researchers measure

Primary outcomes

  1. PK Model Parameter Estimates

    Data obtained from assays of TXA in blood, dose group and patient characteristics; parameter estimates in 2 compartment model includes the clearance of the drug (L/hr).

    Time frame: Different time points ranging from surgery (T0) to 1 day postpartum.

  2. Pharmacodynamics of Tranexamic Acid

    PD model parameters included concentration of TXA causing 50% of maximal fractional inhibition (IC50).

    Time frame: Different time points ranging from surgery (T0) to 1 day postpartum.

Secondary outcomes

  1. Estimated Blood Loss

    Intraoperative blood loss

    Time frame: During surgery

  2. Safety Parameters

    Safety parameters such as adverse events (including nausea/vomiting) and serious adverse events

    Time frame: During surgery, after surgery while in hospital, 2 weeks and 6 weeks postpartum

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2022 (actual). Primary completion is estimated for Oct 2027, 57 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Nov 2026 → Oct 2027 and completion Jun 2027 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2022
First posted
May 12, 2022
StartActual
Dec 28, 2022
Primary completionEst.
Oct 1, 2027was Nov 2026
CompletionEst.
Apr 1, 2028was Jun 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 15, 2026→Oct 1, 2027
Oct 16, 2026
Study completion
Jun 1, 2027→Apr 1, 2028
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Nov 15, 2026→Oct 1, 2027
    Study completion Jun 1, 2027→Apr 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05370820
Lead sponsor
Inova Health Care Services
Responsible party
Homa Ahmadzia, MD (MD, PI, Inova Health Care Services) — Principal investigator
First posted
May 12, 2022
Start date
Dec 28, 2022
Primary completion
Oct 1, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Homa K Ahmadzia, MD
Contact
homa.ahmadzia@inova.org
706-776-6650
Jaclyn Phillips
Contact
Homa K Ahmadzia, MD
principal investigator · Inova Health Care Services

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion